LeBron James, Nikola Jokić reportedly meet over $5bn upstart to rival NBA
The proposed league, spearheaded by Carter, would feature six men's and six women's teams that travel together to eight global cities in a touring format. Inspired by LIV Golf and Formula One, the league aims to offer players equity stakes, something NBA rules currently prohibit for active athletes.
Ražnatović, a powerful figure in European basketball, posted a photo of the meeting on Instagram over the weekend. The caption, tagged in Saint-Tropez, teased: 'The summer of 2025 is the perfect time to make big plans for the fall of 2026.' That photo fueled speculation about a potential team-up between James and Jokić, but sources confirmed to Front Office Sports the meeting was unrelated to the NBA.
Carter began pitching the league earlier this year, with Bloomberg reporting in January that he is seeking to raise $5bn in funding. Backers already include the Singapore government, Saudi Arabia's Public Investment Fund, SC Holdings, UBS and investors such as Skype co-founder Geoff Prentice and former Facebook executive Grady Burnett.
Unlike the WNBA-adjacent Unrivaled league, which allows dual participation, Carter's venture is expected to require full-time commitments, effectively ruling out NBA participation unless league rules change.
The NBA, meanwhile, is pursuing its own expansion into Europe. Commissioner Adam Silver and deputy commissioner Mark Tatum met with UK prime minister Keir Starmer in London last week to discuss plans for a Europe-based NBA league in partnership with Fiba. As part of that effort, the NBA announced that the Orlando Magic and Memphis Grizzlies will play regular-season games in Berlin and London in January 2026.
EuroLeague officials have pushed back against the NBA's expansion talks. 'We said to them, like we said publicly, we don't believe that the new league is something that would help the market,' EuroLeague CEO Paulius Motiejūnas told the Athletic on Tuesday.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Benchmark Co. Maintains Buy Rating on ACM Research (ACMR) Stock
ACM Research, Inc. (NASDAQ:ACMR) is one of the Most Undervalued Semiconductor Stocks to Buy According to Analysts. On June 11, Benchmark Co. analyst Mark Miller maintained a 'Buy' rating on the company's stock and set a price objective of $38.00. The analyst's rating is backed by a combination of factors, which include significant market opportunities and strategic geographic expansion. ACM Research, Inc. (NASDAQ:ACMR)'s commitment to expanding presence in the US and Korea, together with established operations in Europe, places it for growth. Close-up of a worker wearing protective gear inspecting a silicon wafer in a laboratory. Furthermore, it also tends to benefit from the majority ownership in ACM Shanghai, which happens to be financially rewarding via dividends. The analyst believes that, with a healthy outlook for shipment growth in 2025 as well as a long-term sales model, ACM Research, Inc. (NASDAQ:ACMR) exhibits robust potential for success. ACM Research, Inc. (NASDAQ:ACMR) posted revenues of $172.3 million in Q1 2025, up 13.2%, showcasing increased sales of single wafer cleaning, Tahoe and semi-critical cleaning equipment and ECP (front-end and packaging), furnace, and other technologies. While we acknowledge the potential of ACMR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
Argus Raises PT on NXP Semiconductors N.V. (NXPI) Stock, Maintains Buy
NXP Semiconductors N.V. (NASDAQ:NXPI) is one of the Most Undervalued Semiconductor Stocks to Buy According to Analysts. On July 23, Argus analyst Jim Kelleher lifted the price objective on the company's stock to $270 from $235, while keeping a 'Buy' rating after the Q2 2025 report, as reported by The Fly. While the company's guidance was above the estimates, the stock traded lower due to tariff and macroeconomic concerns, opines the analyst. A close-up of a semiconductor component, highlighting its complex design. NXP Semiconductors N.V. (NASDAQ:NXPI)'s guidance for Q3 2025 demonstrates the combination of an emerging cyclical improvement in its core end markets and the performance of the company-specific growth drivers. NXP Semiconductors N.V. (NASDAQ:NXPI) continues to fuel strong profitability and earnings through the strengthening of its competitive portfolio and by aligning the wafer fabrication footprint consistent with its hybrid manufacturing strategy. The company announced the completion of acquisition of TTTech Auto, which is a leader in innovating unique safety-critical systems and middleware for software-defined vehicles (SDVs). The open and modular offering of the NXP CoreRide platform and TTTech Auto's MotionWise safety middleware supports the automakers in overcoming software and hardware integration barriers. While we acknowledge the potential of NXPI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
Cleveland Guardians Pitcher Nic Enright Earns First Career Save While Undergoing Cancer Treatment
NEED TO KNOW Cleveland Guardians rookie pitcher Nic Enright earned his first career MLB save on Monday night Enright is also in the midst of treatment for Hodgkin lymphoma 'I've gone through a lot of adversity," Enright told reporters after the game, reflecting on the career highlightCleveland Guardians pitcher Nic Enright's hallmark year became even more memorable Monday night. Enright, 28, earned the first save of his Major League Baseball career after helping his team hold on to a 7-6 win over the New York Mets on Monday, Aug. 4, as he continues to juggle cancer treatments with baseball amid his storybook rookie season. 'What a cool night,' Guardians manager Stephen Vogt reflected after the game, according to 'His first career save. He was outstanding. Nic is such a great kid, what he has been through in his personal life, nothing is going to rattle him.'Vogt told reporters he took the scene in as the final out landed in right fielder Nolan Jones' glove, ending the game and giving Enright his monumental career moment."He was almost crying on the field just now," Vogt said, according to ESPN. "If you read his story, it's pretty inspirational." Enright was drafted by the Guardians in 2019 after a successful college career at Virginia Tech. The Richmond, Va., native was claimed by the Miami Marlins in 2022 during the MLB's annual Rule 5 Draft, but was diagnosed with Hodgkin lymphoma just 19 days later. Enright began immunotherapy treatments in 2023, according to ESPN, and faltered on the mound in Miami's minor league system, soon getting released and rejoining Cleveland where he began to rebuild towards his dream of making the MLB. Something clicked for the relief pitcher in 2024, notching an eye-catching 1.06 ERA with Cleveland's top minor league club and earning himself a shot at the MLB in early 2025. He made his major league debut with the Guardians in May and has since proved to be a reliable presence for the team's otherwise tumultuous bullpen with a 2.01 ERA over 19 appearances. But none of them compared to Monday night. 'I've gone through a lot of adversity — just everything that has gone on,' Enright said after earning the save, according to crediting his wife Erin for helping him get through treatment in recent years. 'I reflect on those moments. I think that helps being able to slow the game down because it hasn't exactly been a red-carpet rollout for my career trajectory.' Enright is scheduled to receive his final cancer treatment in November, shortly after the 2025 MLB season comes to a close, according to ESPN. Read the original article on People
